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Rationale: Seizure clusters may be related to Sudden Unexpected Death in Epilepsy
(SUDEP). Two or more generalized convulsive seizures (GCS) were captured during
video electroencephalography in 7/11 (64%) patients with monitored SUDEP in the
MORTEMUS study. It follows that seizure clusters may be associated with epilepsy
severity and possibly with SUDEP risk. We aimed to determine if electroclinical seizure
features worsen from seizure to seizure within a cluster and possible associations
between GCS clusters, markers of seizure severity, and SUDEP risk.
Methods: Patients were consecutive, prospectively consented participants with
drug-resistant epilepsy from a multi-center study. Seizure clusters were defined
as two or more GCS in a 24-h period during the recording of prolonged
video-electroencephalography in the Epilepsy monitoring unit (EMU). We measured
heart rate variability (HRV), pulse oximetry, plethysmography, postictal generalized
electroencephalographic suppression (PGES), and electroencephalography (EEG)
recovery duration. A linear mixed effects model was used to study the difference between
the first and subsequent seizures, with a level of significance set at p < 0.05.
Results: We identified 112 GCS clusters in 105 patients with 285 seizures. GCS lasted
on average 48.7± 19 s (mean 49, range 2–137). PGES emerged in 184 (64.6%) seizures
and postconvulsive central apnea (PCCA) was present in 38 (13.3%) seizures. Changes
in seizure features from seizure to seizure such as seizure and convulsive phase durations
appeared random. In grouped analysis, some seizure features underwent significant
deterioration, whereas others improved. Clonic phase and postconvulsive central apnea
(PCCA) were significantly shorter in the fourth seizure compared to the first. By contrast,
duration of decerebrate posturing and ictal central apnea were longer. Four SUDEP cases
in the cluster cohort were reported on follow-up.
Ochoa-Urrea et al. Seizure Clusters and SUDEP Risk
Conclusion: Seizure clusters show variable changes from seizure to seizure. Although
clusters may reflect epilepsy severity, they alone may be unrelated to SUDEP risk. We
suggest a stochastic nature to SUDEP occurrence, where seizure clusters may be more
likely to contribute to SUDEP if an underlying progressive tendency toward SUDEP has
matured toward a critical SUDEP threshold.
Keywords: SUDEP, seizure cluster, generalized convulsive seizure, epilepsy, video-EEG (VEEG) monitoring
INTRODUCTION
Seizure clusters occur frequently in patients with epilepsy (PWE).
Their frequency ranges from 22–43% in an outpatient setting
(1, 2) and occurs in up to 83% in inpatient settings (3). Frequency
also depends on the definition used and the population targeted
(4). Seizure clusters are usually defined as repetitive and closely
grouped seizures whose pattern of occurrence deviates from
an expected distribution (5, 6). However, a unified operational
definition has not been established (4, 6) Definitions vary from
study to study, including: ≥3 seizures in 24 h (1, 2, 4, 7–13),
≥2 in 24 h (14), and 2–4 seizures in <48 h (15). Seizure clusters
are associated with an increased risk of status epilepticus and
hospitalizations, and are deleterious for quality of life of PWE
(7, 16). In addition, seizure clusters are associated with increased
mortality and are seen as an adverse event in the epilepsy
monitoring unit (EMU) (2, 17, 18).
In the landmark mortality in epilepsy monitoring unit study
(MORTEMUS), two or more generalized convulsive seizures
(GCS) were captured during video electroencephalography
(VEEG) in 7/11 (64%) patients with VEEG monitored SUDEP,
and in 3/9 (33%) patients in near-SUDEP (19). Thus, the
occurrence of a cluster of GCS has been speculated to be a
risk factor for SUDEP. We hypothesized that if GCS clusters
are a SUDEP risk factor, electroclinical scrutiny of consecutive
GCS may indicate increasing seizure severity. We aimed
to determine if there is worsening of electroclinical seizure
features from seizure to seizure within a cluster and possible




Patients were consecutive, prospectively consented participants
in the National Institute of Neurological Disorders and Stroke
(NINDS) Center for SUDEP Research’s Autonomic and Imaging
Biomarkers of SUDEP multicenter project (U01- NS090407),
its preliminary phase, the Prevention and Risk Identification
of SUDEP Mortality (PRISM) project (P20NS076965) and,
prospectively consented participants from Memorial Hermann
Hospital Epilepsy Monitoring Unit (Houston, Texas). Patients
with drug-resistant epilepsy (failure of adequate trials of ≥2
antiepileptic medications) (20) undergoing VEEG evaluation
in the EMU of participating centers from September 2011
until April 2020 were studied. We included patients with
VEEG recorded GCS clusters, including generalized tonic clonic
seizures, focal to bilateral tonic-clonic seizures, and focal-onset
motor bilateral clonic seizures (21). Exclusion criteria were status
epilepticus and obscured or unavailable video.
Data Collection and Definitions
Demographic and clinical data were collected. A GCS cluster was
defined as two or more GCS in a 24 h period (14). Epileptogenic
zone was classified as generalized (genetic generalized epilepsy in
all cases), focal, both, or unknown (22). State of consciousness
was defined as either awake or asleep according to Tatum,
2014 (23). Clinical seizure duration was determined by the
time between first and last semiological ictal sign, and EEG
duration was determined by the time between EEG onset and
offset. GCS duration was defined as time from onset of bilateral
motor signs of tonicity or clonicity to clinical seizure end. The
duration of GCS was further divided into phases according to
ictal semiology as previously described (24): a tonic phase, a
jittery phase (also called vibratory period) and a clonic phase. In
addition, tonic phase semiology was classified into 4 categories,
based on a modified classification proposed by previous authors,
(25) in ictal decerebrate, decorticate, hemi-decerebrate and
absence of tonic phase. Early nursing intervention was defined
as oxygen administration or suction applied during the seizure
or within 5 s of seizure termination (25). The impact of anti-
seizure medication (ASM) changes on electroclinical features
was assessed. ASM changes were collected as tapering (gradual
decrease in medication), withdrawal (complete cessation of
medication), increase or resumption of medication, and no
change. Administration of rescue medication was determined
as the administration of IV benzodiazepines and/or IV bolus of
ASM during or after a seizure.
Patients underwent prolonged surface VEEG monitoring
with the 10–20 international electrode system or invasive
VEEG with subdural electrodes, depth electrodes or stereoEEG.
Peripheral capillary oxygen saturation (SpO2) and heart rate were
monitored. SpO2 <90% was considered hypoxemia. Breathing
rate was assessed between 2min pre-ictally and 3min after
clinical seizure end through careful composite analysis of
inductance plethysmography, EEG breathing artifact, visually
inspected thoracoabdominal excursions, and auditory breathing
information. Central apnea was defined as ≥1 missed breaths
without any other explanation (i.e., speech, movement, or
intervention). Ictal central apnea (ICA) was defined as apnea
during non-convulsive seizure or apnea occurring in the pre-
convulsive phase of GCS (26). Post-convulsive central apnea
(PCCA) referred to apnea after a GCS (26). Postictal generalized
EEG suppression (PGES) was defined according to Lhatoo
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et al. (27). Presence and duration of postictal generalized EEG
suppression (PGES) were determined by visual analysis. Presence
and duration of postictal EEG burst suppression were also
determined. Combined PGES and burst suppression, following
PGES, made up the EEG recovery duration. Heart rate variability
(HRV) was assessed using the LabChart HRV module (LabChart
Pro 8 software; ADInstruments, Sydney, Australia). For a detailed
description of the data collection and definitions please refer to
the Supplementary Material.
Statistical Analysis
Summary statistics were reported as mean ± standard deviation
(SD), median with range, and frequency with percentage. For
continuous outcomes, linear mixed effects models were used to
study the difference between the first and subsequent seizures
while accounting for the within-cluster correlation. Empirical
covariance estimators were used for robust inferences. For
binary outcomes, generalized linear mixed effects models were
used, with binary distribution and logit link. Each model was
adjusted for sex, age, epilepsy duration, epileptogenic zone, early
nursing intervention (early O2 administration and suction) and
administration of rescue medication. Because the percentage
of clusters composed of five and seven seizures was low, we
performed the mixed model until the 4th seizure and excluded
the 5th, 6th, and 7th seizures from the analysis. The level of
significance was set at p < 0.05. Statistical analysis was done with
SAS software version 9.4 (Cary, NC).
RESULTS
One hundred and twelve GCS clusters were identified in 105
patients with 285 seizures. Three patients had two clusters
and two patients had three clusters during different EMU
admissions. The remainder had one cluster only. Thirteen
(11.6%) clusters occurred during invasive EEG. Mean age was
35.9 ± 14 years (median 33, range 12–69), 47% were female,
and mean epilepsy duration was 16.3 ± 11.6 (14, 0.08–43)
years. Fifty-six (53.33%) patients had ≥3 GCS per year, and
35 (33.33%) had <3 GCS per year. Sixteen (15.2%) patients
had a history of seizure clusters. Fifty-nine percent of seizures
occurred during sleep. The mean inter-seizure interval was 6.52 h
± 6.12 (3.78, 0.05–23.62). The epileptogenic zone was most
frequently temporal lobe, followed by frontal lobe (Table 1).
Average clinical seizure duration was 93.6 ± 44.7 s (84.5,
28–393), average EEG seizure duration was 105.7 s ± 50.5 s
(94, 38–516) and the GCS phase lasted on average 48.7 ±
19 s (49, 2–137). PGES was present in 184 (64.6%) seizures,
lasting on average 36.84 s ± 20.98 (35, 2–135) and PCCA was
present in 38 (13.33%) seizures lasting 10.74 s ± 6.99 (8, 3–26).
Electroclinical seizure features and their respective durations are
shown in Table 2.
There were 70 clusters (66.67%) with two seizures, 30 (28.57%)
with three seizures, six clusters (5.71%) with four seizures, five
clusters (4.76%) with five seizures and one cluster (0.95%) with
seven seizures.
TABLE 1 | Epileptogenic zone.
Variable Patients, n = 105 (%) Cluster, n = 112 (%)
Epileptogenic zone
Generalized 10 (9.5) 10 (8.9)
Focal 93 (88.6) 100 (89.3)
Temporal 37 (39.8) 38 (38)
Bitemporal 13 (13.9) 13 (13)
Frontal 19 (20.4) 22 (22)
Parietal 1 (1) 1 (1)
Insula 1 (1) 1 (1)
Multifocal 13 (13.9) 13 (13)
Lateralized 9 (9.7) 12 (12)
Unknown 2 (1.9) 2 (1.8)
Lateralization of epilepsy
Left 40 (38.1) 43 (38.4)
Right 26 (24.8) 29 (25.9)
Generalized 10 (9.5) 10 (8.9)
Bilateral 27 (25.7) 28 (25)
Unknown 2 (1.9) 2 (1.8)
n, number.
TABLE 2 | Seizure features and their durations.
Seizure feature Seizures
n = 285 (%)
Average
duration (s)
SD (s) Range (s)
Tonic phase 181 (63.5) 7.66 3.96 (2, 22)
Jittery phase 230 (80.7) 10.30 7.50 (1, 41)
Clonic phase 284 (99.6) 37.08 17.09 (5, 130)
Decerebration 130 (45.6) 16.07 11.58 (1, 54)
Decortication 65 (22.8) 15.89 11.19 (2, 50)
PGES 183 (64.2) 36.84 21.04 (2, 135)
Hypoxemia postGCS 84 (29.5) 83.31 46.71 (4, 310)
EEG recovery 185 (64.9) 74.88 60.46 (2, 354)
PCCA 35 (12.3) 10.74 7.09 (3, 37)
ICA 72 (38.9) 17.54 12.95 (5, 74)
s, seconds; n, number; PGES, post-ictal generalized electroencephalographic
suppression; EEG, electroencephalographic; PCCA, post-convulsive central apnea; ICA,
ictal central apnea.
Electroclinical Characteristics
We did a group analysis to compare electroclinical features
of the first seizure with subsequent seizures, adjusting for
sex, age, epilepsy duration, epileptogenic zone, administration
of rescue medication, early administration of oxygen and
early suctioning (early nursing intervention). No significant
differences were found in clinical or EEG seizure duration,
tonic phase duration, GCS duration, PGES duration and EEG
recovery (Table 3). Concerning HRV, there were no statistically
significant differences between seizures. In addition, state of
consciousness (awake or asleep), SpO2 recovery, presence of
decerebrate posturing, total hypoxemia duration, and presence
of PGES did not show differences between seizures. Seizure-
to-seizure comparisons of clinical seizure durations and GCS
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TABLE 3 | Comparison of electroclinical features of first seizure with each
subsequent seizure in a cluster.
Seizure feature Seizure # Estimate Standard Error p-value
Clinical duration 1 0
2 1.91 5.39 0.725
3 −0.62 5.51 0.911
4 2.04 6.96 0.770
EEG duration 1 0
2 −1.57 7.05 0.824
3 0.48 7.24 0.948
4 −0.49 7.97 0.951
Decerebration duration 1 0
2 1.06 1.21 0.386
3 0.79 2.10 0.710
4 7.22 1.15 <0.0001
Tonic phase duration 1 0
2 0.75 0.60 0.219
3 1.87 1.07 0.087
4 5.96 3.15 0.064
Clonic phase duration 1 0
2 −2.19 2.54 0.390
3 −6.05 3.17 0.059
4 −11.87 3.63 0.002
GCS duration 1 0
2 −0.62 2.35 0.792
3 −2.68 2.97 0.369
4 −5.41 3.86 0.164
PGES duration 1 0
2 −2.35 3.77 0.535
3 −5.43 3.69 0.147
4 −10.98 17.26 0.527
EEG recovery 1 0
2 −18.63 10.81 0.091
3 −11.54 16.29 0.482
4 −49.71 26.09 0.062
PCCA duration 1 0
2 −2.13 4.30 0.654
3 0.94 1.63 0.606
4 −7.49 1.70 0.022
ICA duration 1 0
2 3.16 2.72 0.255
3 5.42 4.14 0.201
4 10.79 3.53 0.005
EEG, electroencephalographic; GCS, generalized convulsive seizure; PGES, post-ictal
generalized electroencephalographic suppression; PCCA, post-convulsive central apnea;
ICA, ictal central apnea. Bold values indicate p < 0.05.
durations showed apparently random variations representing
either improvement, deterioration or no change. We depicted
the variation in seizure duration for clinical seizure duration and
GCS duration as an example (Figure 1). As inferred from the
graphs in the figure, seizures tended to have the same or random
durations throughout the cluster.
Duration of clonic phase and PCCA duration were
significantly shorter in the 4th seizure as compared to the
first one (Table 3), p = 0.002 and p = 0.022, respectively. On
the other hand, duration of decerebrate posturing (p < 0.0001)
and ictal central apnea (ICA) (p = 0.005) were longer in the 4th
seizure. With both parameters we found a progressive increase
in duration with subsequent seizures.
Anti-seizure Medications
For 217 (76%) seizures we had information on changes in anti-
seizure medications (ASM) during the EMU admission. Of these,
80 (36.9%) seizures occurred during medication taper, 68 (31.3%)
during medication withdrawal, 66 (30.4%) during resumption or
increase of ASM and three (1.38%) seizures occurred with no
change in ASM. We grouped the changes in ASM into those
who had taper or withdrawal and those who had increase or
no change. We compared both groups and found no statistically
significant differences with regards to electroclinical features
(Supplementary Table 1). However, the group with taper or
withdrawal of ASM were less likely to have PGES. Rescue
medication, either a benzodiazepine, an intravenous bolus of
ASM or both, was given after 34 seizures in 25 clusters.
SUDEP Cases
Four cases of definite/probable SUDEP were established during
follow-up. They died between 9 months and 5.5 years after
admission. Two of them were found unresponsive in bedroom
and for the other two there is no current information about
the circumstances of death. Of these cases, only one had a
known history of seizure clusters before the EMU evaluation.
Average age was 49.25 ± 10.15 years (51.5, 33–61) with a
duration of epilepsy of 34.5 ± 7.5 years (35.5, 24–43). They
had between 12 and 24 GCS in the prior year. There were no
consistent electroclinical characteristics among them. However,
two had PGES >50 s. The mean intra-cluster inter-seizure
interval for SUDEP patients was 5.14± 5.02 h (3.24, 1.63–14.82).
In comparison with patients who did not die, there was no
difference in the inter-seizure interval (p= 0.59).
DISCUSSION
Our prospective study of GCS in the EMU suggest that the
markers of seizure severity in seizure clusters, in each consecutive
seizure, change randomly. Some markers show improvement
while others either stay the same or deteriorate with subsequent
seizures. This heterogeneity suggests that clusters alone may
not predispose to SUDEP, but that their timing in relation
to the overall course of a patient’s epilepsy may be more
important for mortality risk. Thus, the course of SUDEP may
be a stochastic, rather than probabilistic process, where an
underlying progressive increase in SUDEP risk accrues over time.
Seizure clusters early in this progression pose less risk than
clusters late in the process (Figure 2, model B). TheMORTEMUS
study suggested that seizure clusters were important premortem
phenomena (19), although this was not a controlled observation,
and no electroclinical characterization of seizure clusters was
carried out. Our study suggests that seizure clusters in themselves
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FIGURE 1 | Clinical seizure and convulsive phase durations in patients with at least four seizures in a cluster and for SUDEP cases. Durations for clinical seizure (A)
and for GCS (B) are depicted. Each line represents a cluster and each point represents the duration in seconds for a specific seizure in the cluster.
may not be risk factors for death. Known risk factors of
younger age of onset of epilepsy and longer duration of epilepsy
may indicate that the underlying tendency toward SUDEP is
a progressive phenomenon (28–30). We found no significant
effect of duration of epilepsy and age of onset of epilepsy
on tendency to worsening of electroclinical markers of seizure
severity. Supporting the notion that clusters may not be related
to SUDEP risk is the PCDH19-Related Epilepsy Syndrome. It
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FIGURE 2 | Models of seizure clusters and SUDEP risk. Each square, dot or triangle represents a seizure. A proposed SUDEP phenotype is represented in black,
where sporadic seizures occur over years, eventually culminating in SUDEP. Model A proposes that clusters are important for risk of SUDEP, regardless of underlying
tendency whereas Model B denotes that risk is only enhanced if the underlying risk has also progressed toward a hypothetical SUDEP “threshold.” Our data suggests
that model B may be more likely than model A.
is a childhood onset epilepsy syndrome characterized by seizure
clusters (31). To the best of our knowledge, no case of SUDEP
related to PCDH19 has been reported in the literature.
The four prospectively ascertained SUDEP patients in our
study had very long durations of epilepsy (24–43 years), and the
time from recorded clusters to SUDEP ranged from 9 months
to 5.5 years. None of the patients were reported to have seizure
clusters around the time of SUDEP. Two patients had a very high
frequency of GCS (up to 24 per year) and two had prolonged
PGES (>50 s); both have been proposed as risk factors for SUDEP
(27, 32). However, the clusters in our SUDEP cases behaved very
similarly to clusters in the rest of our study population.
GCS are the most important risk factor for SUDEP (32). A
recent study suggested that GCS become dramatically lethal when
they occur under circumstances such as in night time, sleeping
alone, living alone and prone position (33). In addition, if risk
factors such as living alone and the presence of GCS could be
modified, a great proportion (69%) of SUDEP cases could be
prevented (34). These observations suggest that GCS clusters
occurring in well-supervised environments such as the EMU, like
in this study, are unlikely to cause SUDEP.
On examination of electroclinical seizure features, we
found no progressive increase in clinical or electrographic
seizure duration. There was also no increase in various
seizure severity markers such as tonic phase and convulsive
phase durations, presence of decerebrate posturing, hypoxemia
duration, SpO2 recovery, and presence of PGES. Some patients
showed no significant changes in seizure features from seizure
to seizure, whereas others either improved or deteriorated.
Within individuals, each subsequent seizure could either show
improvement or deterioration in seizure severity, suggesting
random variations.
On the other hand, in grouped analysis, durations of clonic
phase and PCCA were significantly shorter in subsequent
seizures. These findings may indicate faster recovery with
subsequent seizures, from a clinical and respiratory standpoint,
and thus an adaptive process that is perhaps protective against
SUDEP risk. It is possible that seizure termination mechanisms
are enhanced with repetitive seizures (35, 36), and lead to faster
recovery of respiratory drive and to a shorter clonic phase.
However, in contrast to a previous study that found the last
seizure in a cluster to be longer, we failed to find significant
differences in terms of clinical and EEG seizure duration between
the first and the fourth seizure (3) (Figure 1). The difference
in these findings could reflect dissimilarities in seizure cluster
definition and the type of seizures explored. We only included
GCS in our study, while other studies have included non-
convulsive seizures within the cluster (3). We chose to include
only GCS since these events are directly related to SUDEP risk
(32, 37). In addition, a study found that in patients who later
developed SUDEP, heart rate tended to increase with subsequent
seizures in a clusters (38). We evaluated HRV and we did not find
any changes in these parameters with subsequent seizures within
a cluster.
Interestingly, in grouped analysis, we found some seizure
features to worsen, namely duration of decerebrate posturing
and ICA duration. Both decerebrate posturing duration and
ICA duration are putative markers of seizure severity (39,
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40). Decerebrate posturing has been associated with PGES, a
proposed SUDEP biomarker (40). Similarly, prolonged ICA
(>60 s) has been associated with severe hypoxemia (39).
Although, ICA was longer with each seizure, the average
duration of ICA was short (17.54 s). Thus, a much larger
number of seizure clusters and patients may be needed
for study to throw light on the apparently contradictory
improvements in some seizure features and deterioration
in others.
With regards to ASM, we found that tapering or withdrawal
did not influence electroclinical features of a seizure. PGES
was more likely to happen in the group with increase or no
change in medication. However, PGES duration did not show
any difference.
Limitations of our study include difficulty in using a
standardized definition of seizure clusters since no consensus
currently exists. We chose the definition of two or more
GCS in 24 h since the MORTEMUS study observed that
patients with SUDEP had two or more seizures before death
(19). Clusters in our sample were created by medication
discontinuation in the EMU and so they may not behave
as seizure clusters in ambulatory PWE. Thus, these may
be biologically distinct phenomena. In addition, we did
not include in the analysis non-convulsive seizures. Hence,
it is not possible to ascertain whether other seizure
types could potentially affect the severity of physiologic
changes seen in a cluster that also include GCS. We
acknowledge that there was a low number of SUDEP cases
in our sample.
CONCLUSIONS
If there is no evidence of convincing, progressive deterioration
of seizure severity parameters with subsequent seizures, then, is
there a role for clusters in SUDEP? The findings of this study
suggest that the occurrence of clusters alone does not set the stage
for SUDEP with each successive seizure, in quantifiable terms.
We therefore hypothesize that SUDEP may be the culmination
of underlying disease progression (41) that reaches a critical
SUDEP threshold; seizure clusters may only become important
for enhanced mortality risk if they occur around this threshold.
In conclusion, clustering failed to show evidence of clinical
or electroencephalographic deterioration with each seizure that
would explain why seizure clusters may lead to SUDEP, as
found by the MORTEMUS study (19). Although clusters may
reflect epilepsy severity, their occurrence by themselves may
be unrelated to SUDEP risk, and may require underlying
progression toward a SUDEP threshold before finally leading
to SUDEP.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation.
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by Case Western Reserve University and University
Hospitals, as part of NIH/NINDS Center for SUDEP Research
study (U01 NS090405, U01 NS090406, U01 NS090407). Written
informed consent to participate in this study was provided by the
participants’ legal guardian/next of kin.
AUTHOR CONTRIBUTIONS
MO-U: major role in the acquisition and analysis of data,
design and conceptualized the study, interpreted the data, and
drafted the manuscript for intellectual content. NL and SL:
design and conceptualized study, interpreted the data, and
revised the manuscript for intellectual content. LV, SJ-O, MR,
JPH, MD, JH, NH, VR-M, CS, JO, and ST: data acquisition.
LZ: analysis of data, statistical analysis, and reviewed the
manuscript for intellectual content. RS, DF, MN, LA, BG, SS,
RH, BD, LB, OD, GR, and G-QZ: revised the manuscript for
intellectual content.
FUNDING
This study was funded by the Center for SUDEP
Research: NIH/NINDS U01-NS090405, U01 NS090406,
and U01 NS090407.
SUPPLEMENTARY MATERIAL




1. Haut SR, Lipton RB, LeValley AJ, Hall CB, Shinnar S. Identifying
seizure clusters in patients. Neurology. (2005) 19:1313–5.
doi: 10.1212/01.wnl.0000180685.84547.7f
2. Sillanpää M, Schmidt D. Seizure clustering during drug treatment affects
seizure outcome and mortality of childhood-onset epilepsy. Brain. (2008)
131:938–44. doi: 10.1093/brain/awn037
3. Ferastraoaru V, Schulze-Bonhage A, Lipton RB, Dümpelmann M, Legatt AD,
Blumberg J, et al. Termination of seizure clusters is related to the duration of
focal seizures. Epilepsia. (2016) 57:889–95. doi: 10.1111/epi.13375
4. Haut SR. Seizure clusters: characteristics and treatment. Curr
Opin Neurol. (2015) 28:143–50. doi: 10.1097/WCO.00000000000
00177
5. Dreifuss FE, Rosman NP, Cloyd JC, Pellock JM, Kuzniecky RI, Lo WD, et al.
A comparison of rectal diazepam gel and placebo for acute repetitive seizures.
N Engl J Med. (1998) 338:1869–75. doi: 10.1056/NEJM199806253382602
6. Jafarpour S, Hirsch LJ, Gaínza-Lein M, Kellinghaus C, Detyniecki K. Seizure
cluster: definition, prevalence, consequences, and management. Seizure.
(2019) 68:9–15. doi: 10.1016/j.seizure.2018.05.013
7. Haut SR, Shinnar S, Moshé SL. Seizure clustering: risks and outcomes.
Epilepsia. (2005) 46:146–9. doi: 10.1111/j.0013-9580.2005.29004.x
Frontiers in Neurology | www.frontiersin.org 7 February 2021 | Volume 12 | Article 643916
Ochoa-Urrea et al. Seizure Clusters and SUDEP Risk
8. Scholly J, Bartolomei F, Valenti-Hirsch MP, Boulay C, De Saint Martin A,
Timofeev A, et al. Atonic seizures in children with surgically remediable
epilepsy: a motor system seizure phenotype? Epileptic Disord. (2017) 19:315–
26. doi: 10.1684/epd.2017.0930
9. Yen D-J, Chen C, Shih Y-H, Guo Y-C, Liu L-T, Yu H-Y, et al.
Antiepileptic drug withdrawal in patients with temporal lobe epilepsy
undergoing presurgical video-EEG monitoring. Epilepsia. (2008) 42:251–5.
doi: 10.1046/j.1528-1157.2001.15100.x
10. Chen B, Choi H, Hirsch LJ, Katz A, Legge A, Wong RA, et al. Prevalence and
risk factors of seizure clusters in adult patients with epilepsy. Epilepsy Res.
(2017) 133:98–102. doi: 10.1016/j.eplepsyres.2017.04.016
11. Rose AB, McCabe PH, Gilliam FG, Smith BJ, Boggs JG, Ficker
DM, et al. Occurrence of seizure clusters and status epilepticus
during inpatient video-EEG monitoring. Neurology. (2003) 60:975–8.
doi: 10.1212/01.WNL.0000053748.83309.28
12. Di Gennaro G, Picardi A, Sparano A, Mascia A, Meldolesi GN, Grammaldo
LG, et al. Seizure clusters and adverse events during pre-surgical video-EEG
monitoring with a slow anti-epileptic drug (AED) taper. Clin Neurophysiol.
(2012) 123:486–8. doi: 10.1016/j.clinph.2011.08.011
13. Martinez C, Sullivan T, Hauser WA. Prevalence of acute repetitive
seizures (ARS) in the United Kingdom. Epilepsy Res. (2009) 87:137–43.
doi: 10.1016/j.eplepsyres.2009.08.006
14. Fisher RS, Bartfeld E, Cramer JA. Use of an online epilepsy diary
to characterize repetitive seizures. Epilepsy Behav. (2015) 47:66–71.
doi: 10.1016/j.yebeh.2015.04.022
15. Asadi-Pooya AA, Nei M, Sharan A, Sperling MR. Seizure clusters in drug-
resistant focal epilepsy. Epilepsia. (2016) 57:e187–90. doi: 10.1111/epi.13465
16. Penovich PE, Buelow J, Steinberg K, Sirven J, Wheless J. Burden of seizure
clusters on patients with epilepsy and caregivers. Neurologist. (2017) 22:207–
14. doi: 10.1097/NRL.0000000000000140
17. Fahoum F, Omer N, Kipervasser S, Bar-Adon T, Neufeld M. Safety in the
epilepsy monitoring unit: a retrospective study of 524 consecutive admissions.
Epilepsy Behav. (2016) 61:162–7. doi: 10.1016/j.yebeh.2016.06.002
18. Rheims S, Ryvlin P. Patients’ safety in the epilepsy monitoring unit. Curr Opin
Neurol. (2014) 27:213–8. doi: 10.1097/WCO.0000000000000076
19. Ryvlin P, Nashef L, Lhatoo SD, Bateman LM, Bird J, Bleasel A, et al.
Incidence andmechanisms of cardiorespiratory arrests in epilepsymonitoring
units (MORTEMUS): a retrospective study. Lancet Neurol. (2013) 12:966–77.
doi: 10.1016/S1474-4422(13)70214-X
20. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern
G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad
hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia.
(2009) 51:1069–77. doi: 10.1111/j.1528-1167.2009.02397.x
21. Fisher RS, Cross JH, French JA, Higurashi N, Peltola J, Roulet E, et al.
Operational classification of seizure types by the International League Against
Epilepsy : position paper of the ILAE commission for classification and
terminology. Epilepsia. (2017) 58:522–30. doi: 10.1111/epi.13670
22. Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto
L, et al. ILAE classification of the epilepsies: position paper of the ILAE
commission for classification and terminology. Epilepsia. (2017) 58:512–21.
doi: 10.1111/epi.13709
23. Tatum WO. Normal adult EEG. In: Ebersole JS, Husain AM, Nordli
DR Jr, editors. Current Practice of Clinical Electroencephalography. 4th ed.
Philadelphia: Wolters Kluwer (2014). p. 90–124.
24. Lhatoo SD, Luders HO. Secondary generalized tonic–clonic seizures (54b).
In: Luders HO, editor. Textbook of Epilepsy Surgery. London, UK: Informa
Healthcare (2008). p. 492–500.
25. Alexandre V, Mercedes B, Valton L, Maillard L, Bartolomei F, Szurhaj
W, et al. Risk factors of postictal generalized EEG suppression
in generalized convulsive seizures. Neurology. (2015) 85:1598–603.
doi: 10.1212/WNL.0000000000001949
26. Vilella L, Lacuey N, Hampson JP, Rani MRS, Loparo K, Sainju RK,
et al. Incidence, recurrence, and risk factors for peri-ictal central apnea
and sudden unexpected death in epilepsy. Front Neurol. (2019) 10:1–13.
doi: 10.3389/fneur.2019.00166
27. Lhatoo SD, Faulkner HJ, Dembny K, Trippick K, Johnson C, Bird
JM. An electroclinical case-control study of sudden unexpected
death in epilepsy. Ann Neurol. (2010) 68:787–96. doi: 10.1002/ana.
22101
28. Hitiris N, Suratman S, Kelly K, Stephen LJ, Sills GJ, Brodie MJ.
Sudden unexpected death in epilepsy: a search for risk factors.
Epilepsy Behav. (2007) 10:138–41. doi: 10.1016/j.yebeh.2006.
11.010
29. Walczak TS, Leppik IE, D’Amelio M, Rarick J, So E, Ahman P, et al. Incidence
and risk factors in sudden unexpected death in epilepsy. Neurology. (2001)
56:519–25. doi: 10.1212/WNL.56.4.519
30. Nilsson L, Farahmand B, Persson P-G, Thiblin I, Tomson T. Risk factors for
sudden unexpected death in epilepsy: a case control study. Lancet. (1999)
353:888–93. doi: 10.1016/S0140-6736(98)05114-9
31. Samanta D. PCDH19-related epilepsy syndrome: a
comprehensive clinical review. Pediatr Neurol. (2020) 105:3–9.
doi: 10.1016/j.pediatrneurol.2019.10.009
32. Harden C, Tomson T, Gloss D, Buchhalter J, Cross JH, Donner
E, et al. Practice guideline summary: sudden unexpected death in
epilepsy incidence rates and risk factors. Neurology. (2017) 88:1674–80.
doi: 10.1212/WNL.0000000000003685
33. Sveinsson O, Andersson T, Carlsson S, Tomson T. Circumstances of SUDEP:
a nationwide population-based case series. Epilepsia. (2018) 59:1074–82.
doi: 10.1111/epi.14079
34. Sveinsson O, Andersson T, Mattsson P, Carlsson S, Tomson T.
Clinical risk factors in SUDEP. Neurology. (2020) 94:e419–29.
doi: 10.1212/WNL.0000000000008741
35. Lado FA, Moshé SL. How do seizures stop? Epilepsia. (2008) 49:1651–64.
doi: 10.1111/j.1528-1167.2008.01669.x
36. Timofeev I, Steriade M. Neocortical seizures: initiation,
development and cessation. Neuroscience. (2004) 123:299–336.
doi: 10.1016/j.neuroscience.2003.08.051
37. Faingold CL, Evans MS. Pathophysiology of generalized tonic-clonic seizures.
In: Panayiotopoulos CP, editor. Atlas of Epilepsies. London: Springer London
(2010). p. 243–6.
38. Nei M, Ho RT, Abou-Khalil BW, Drislane FW, Liporace J,
Romeo A, et al. EEG and ECG in sudden unexplained death in
epilepsy. Epilepsia. (2004) 45:338–45. doi: 10.1111/j.0013-9580.2004.
05503.x
39. Lacuey N, Zonjy B, Hampson JP, Rani MRS, Zaremba A, Sainju RK, et al. The
incidence and significance of periictal apnea in epileptic seizures. Epilepsia.
(2018) 59:573–82. doi: 10.1111/epi.14006
40. Vilella L, Lacuey N, Hampson JP, Zhu L, Omidi S, Ochoa-Urrea
M, et al. Association of peri-ictal brainstem posturing with seizure
severity and breathing compromise in patients with generalized convulsive
seizures. Neurology. (2021) 96:e352–65. doi: 10.1212/WNL.00000000000
11274
41. Simeone KA, Hallgren J, Bockman CS, Aggarwal A, Kansal V, Netzel L,
et al. Respiratory dysfunction progresses with age in Kcna1-null mice, a
model of sudden unexpected death in epilepsy. Epilepsia. (2018) 59:345–57.
doi: 10.1111/epi.13971
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2021 Ochoa-Urrea, Lacuey, Vilella, Zhu, Jamal-Omidi, Rani, Hampson,
Dayyani, Hampson, Hupp, Tao, Sainju, Friedman, Nei, Scott, Allen, Gehlbach,
Reick-Mitrisin, Schuele, Ogren, Harper, Diehl, Bateman, Devinsky, Richerson, Zhang
and Lhatoo. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) and the copyright owner(s)
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Neurology | www.frontiersin.org 8 February 2021 | Volume 12 | Article 643916
